Pierre Borgeat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Pierre Borgeat has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Serge Picard
Université Laval, Queébec, Québec, Canada
8 shared publications- Nicolas Flamand
Centre de Recherche de l’Institut Universitaire de Cardiologie et Pneumologie de Québec (IUCPQ), Département de Médecine, Faculté de Médecine, Université Laval, Québec, QC G1V 0A6, Canada
5 shared publications Hendrick Plante
Centre de Recherche en Rhumatologie et Immunologie, Centre de Recherche du CHUQ and Faculté de Médecine, Université Laval, 2705 Boulevard Laurier, Quebec, G1V 4G2, Canada
3 shared publications- Sylvain G. Bourgoin
Laval University
3 shared publications Julie S. Lefebvre
Trudeau Institute, Québec, Québec, Canada
2 shared publications- Marc Pouliot
Axe de Recherche Maladies Infectieuses et Immunitaires, Centre de Recherche du CHU de Québec-Université Laval, Québec, QC, Canada
2 shared publications
Latest Publications
- Open Access
- 25 February 2011
- Published by Wiley in Arthritis & Rheumatism
- Vol. 63 (6) , 1527-1533
Extra domain A of fibronectin primes leukotriene biosynthesis and stimulates neutrophil migration through activation of Toll-like receptor 4
Objective There is increasing evidence of a role for Toll-like receptors (TLRs) in inflammatory arthritis. The extra domain A (ED-A)–containing isoform of fibronectin is generated under pathologic conditions such as rheumatoid arthritis, and ED-A has been identified as an endogenous TLR-4 ligand. Leukotriene B4 (LTB4) and polymorphonuclear neutrophils (PMNs) play a critical role in murine models of inflammatory arthritis. The aim of this study was therefore to investigate the putative effects of ED-A on leukotriene biosynthesis and PMN migration through TLR signaling. Methods The effect of recombinant human ED-A (rhED-A) on leukotriene biosynthesis was evaluated in isolated human blood PMNs and monocytes by high-performance liquid chromatography. The capacity of rhED-A to stimulate PMN migration was evaluated using a transendothelial/matrix migration assay in vitro and the mouse air-pouch model in vivo. Results Recombinant human ED-A efficiently primed the biosynthesis of LTB4 in PMN and monocyte suspensions. This priming effect was dependent on TLR-4 activation, since the TLR-4–signaling inhibitor CLI-095 completely blocked the effect of rhED-A but not that of other TLR ligands (R-848, Pam2CSK4) or cytokines. Moreover, rhED-A stimulated transendothelial migration of PMNs in vitro, which was inhibited by 50–60% with the LTB4 receptor 1 (BLT1) antagonist CP105,696 or the cytosolic phospholipase A2α inhibitor pyrrophenone. In vivo, rhED-A induced a significant PMN recruitment into the air pouch of C3H/HeOuJ mice (expressing functional TLR-4), but not in C3H/HeJ mice (expressing nonsignaling TLR-4). Conclusion These results demonstrate the ability of rhED-A to promote LTB4 biosynthesis and PMN migration through TLR-4 activation, thus providing new insights on TLR-dependent mechanisms of regulation of LTB4 biosynthesis and PMN infiltration in inflammatory joint diseases.
- 25 February 2011
- Published by Wiley in Arthritis & Rheumatism
- Vol. 63 (6) , 1527-1533
Open AccessExtra domain A of fibronectin primes leukotriene biosynthesis and stimulates neutrophil migration through activation of Toll-like receptor 4
Objective There is increasing evidence of a role for Toll-like receptors (TLRs) in inflammatory arthritis. The extra domain A (ED-A)–containing isoform of fibronectin is generated under pathologic conditions such as rheumatoid arthritis, and ED-A has been identified as an endogenous TLR-4 ligand. Leukotriene B4 (LTB4) and polymorphonuclear neutrophils (PMNs) play a critical role in murine models of inflammatory arthritis. The aim of this study was therefore to investigate the putative effects of ED-A on leukotriene biosynthesis and PMN migration through TLR signaling. Methods The effect of recombinant human ED-A (rhED-A) on leukotriene biosynthesis was evaluated in isolated human blood PMNs and monocytes by high-performance liquid chromatography. The capacity of rhED-A to stimulate PMN migration was evaluated using a transendothelial/matrix migration assay in vitro and the mouse air-pouch model in vivo. Results Recombinant human ED-A efficiently primed the biosynthesis of LTB4 in PMN and monocyte suspensions. This priming effect was dependent on TLR-4 activation, since the TLR-4–signaling inhibitor CLI-095 completely blocked the effect of rhED-A but not that of other TLR ligands (R-848, Pam2CSK4) or cytokines. Moreover, rhED-A stimulated transendothelial migration of PMNs in vitro, which was inhibited by 50–60% with the LTB4 receptor 1 (BLT1) antagonist CP105,696 or the cytosolic phospholipase A2α inhibitor pyrrophenone. In vivo, rhED-A induced a significant PMN recruitment into the air pouch of C3H/HeOuJ mice (expressing functional TLR-4), but not in C3H/HeJ mice (expressing nonsignaling TLR-4). Conclusion These results demonstrate the ability of rhED-A to promote LTB4 biosynthesis and PMN migration through TLR-4 activation, thus providing new insights on TLR-dependent mechanisms of regulation of LTB4 biosynthesis and PMN infiltration in inflammatory joint diseases.
- Open Access
- 20 October 2009
- Published by Wiley in The FASEB Journal
- Vol. 24 (2) , 637-647
Toll‐like receptor ligands induce polymorphonuclear leukocyte migration: key roles for leukotriene B 4 and platelet‐activating factor
Activation of toll‐like receptors (TLRs) and polymorphonuclear leukocyte (PMN) accumulation at infection sites are critical events of host defense. The involvement of leukotriene (LT) B 4 and platelet‐activating factor (PAF) in TLR ligand‐induced activation of inflammatory cell functions is essentially unknown. Using an in vitro model of human PMN migration through human endothelial cell monolayers’ we demonstrate that prototypic ligands of TLR1/2, 2/6, 3, 4, 5, and 7/8 promote PMN migration, an effect markedly inhibited by 3 LTB 4 receptor antagonists (70–80% inhibition at 100 nM compared to vehicle‐treated cells), 3 PAF receptor antagonists (20–50% inhibition at 10 nM), 3 LT biosynthesis inhibitors (75–85% inhibition at 100 nM), and 1 cytosolic phospholipase A 2 α (cPLA 2 α) inhibitor (90% inhibition at 1 μM). Accordingly, selected TLR ligands caused Ser505‐phosphorylation of cPLA 2 α and measurable LTB 4 and PAF biosynthesis in the transmigration assay. As negative controls, interleukin‐8‐ and formyl‐methionyl‐leucyl‐phenylalanine‐elicited migration in vitro was not inhibited either by an LTB 4 receptor antagonist or by the cPLA 2 α inhibitor. Finally, LTB 4 and PAF receptor antagonists inhibited (up to ~65% at optimal doses) TLR ligand‐induced PMN infiltration in the mouse air‐pouch model. These studies unravel the critical involvement of de novo LTB 4 and PAF biosynthesis in PMN migration elicited by TLR ligands.—Lefebvre, J. S., Marleau, S., Milot, V., Lévesque, T., Picard, S., Flamand, N., Borgeat, P. Toll‐like receptor ligands induce polymorphonuclear leukocyte migration: key roles for leukotriene B 4 and platelet‐activating factor. FASEB J . 24, 637–647 (2010). www.fasebj.org
- 20 October 2009
- Published by Wiley in The FASEB Journal
- Vol. 24 (2) , 637-647
Open AccessToll‐like receptor ligands induce polymorphonuclear leukocyte migration: key roles for leukotriene B 4 and platelet‐activating factor
Activation of toll‐like receptors (TLRs) and polymorphonuclear leukocyte (PMN) accumulation at infection sites are critical events of host defense. The involvement of leukotriene (LT) B 4 and platelet‐activating factor (PAF) in TLR ligand‐induced activation of inflammatory cell functions is essentially unknown. Using an in vitro model of human PMN migration through human endothelial cell monolayers’ we demonstrate that prototypic ligands of TLR1/2, 2/6, 3, 4, 5, and 7/8 promote PMN migration, an effect markedly inhibited by 3 LTB 4 receptor antagonists (70–80% inhibition at 100 nM compared to vehicle‐treated cells), 3 PAF receptor antagonists (20–50% inhibition at 10 nM), 3 LT biosynthesis inhibitors (75–85% inhibition at 100 nM), and 1 cytosolic phospholipase A 2 α (cPLA 2 α) inhibitor (90% inhibition at 1 μM). Accordingly, selected TLR ligands caused Ser505‐phosphorylation of cPLA 2 α and measurable LTB 4 and PAF biosynthesis in the transmigration assay. As negative controls, interleukin‐8‐ and formyl‐methionyl‐leucyl‐phenylalanine‐elicited migration in vitro was not inhibited either by an LTB 4 receptor antagonist or by the cPLA 2 α inhibitor. Finally, LTB 4 and PAF receptor antagonists inhibited (up to ~65% at optimal doses) TLR ligand‐induced PMN infiltration in the mouse air‐pouch model. These studies unravel the critical involvement of de novo LTB 4 and PAF biosynthesis in PMN migration elicited by TLR ligands.—Lefebvre, J. S., Marleau, S., Milot, V., Lévesque, T., Picard, S., Flamand, N., Borgeat, P. Toll‐like receptor ligands induce polymorphonuclear leukocyte migration: key roles for leukotriene B 4 and platelet‐activating factor. FASEB J . 24, 637–647 (2010). www.fasebj.org
- Open Access
- 30 January 2007
- Published by Wiley in The FASEB Journal
- Vol. 21 (7) , 1575-1585
The Toll‐like receptor 7/8‐ligand resiquimod (R‐848) primes human neutrophils for leukotriene B 4 , prostaglandin E 2 and platelet‐activating factor biosynthesis
Toll‐like receptors (TLR) recognize pathogen‐associated molecular patterns and play important roles in the innate immune system. While single‐stranded viral RNA is the natural ligand of TLR7/TLR8, the imidazoquinoline resiquimod (R‐848) is recognized as a potent synthetic agonist of TLR7/TLR8. We investigated the effects of TLR7/8 activation on lipid mediator production in polymorphonuclear leukocytes exposed to R‐848. Although R‐848 had minimal effects by itself, it strongly enhanced leukotriene B 4 formation on subsequent stimulation by fMLP, platelet‐activating factor, and the ionophore A23187. R‐848 acted via TLR8 but not TLR7 as shown by the lack of effect of the TLR7‐specific ligand imiquimod. Priming with R‐848 also resulted in enhanced arachidonic acid release and platelet‐activating factor formation following fMLP stimulation, as well as enhanced prostaglandin E 2 synthesis following the addition of arachidonic acid. Western blot analysis demonstrated that R‐848 induced the phosphorylation of the cytosolic phospholipase A 2 α, promoted 5‐lipoxygenase translocation and potently stimulated the expression of the type 2 cyclooxygenase. Bafilomycin A1, an inhibitor of endosomal acidification, efficiently inhibited all R‐848‐induced effects. These studies demonstrate that TLR8 signaling strongly promotes inflammatory lipid mediator biosynthesis and provide novel insights on innate immune response to viral infections.—Hattermann K., Picard, S., Borgeat, M., Leclerc, P., Pouliot, M., Borgeat P. The Toll‐like receptor 7/8‐ligand re‐siquimod (R‐848) primes human neutrophils for leuko‐triene B4, prostaglandin E2 and platelet‐activating factor biosynthesis. FASEB J. 21, 1575–1585 (2007)
- 30 January 2007
- Published by Wiley in The FASEB Journal
- Vol. 21 (7) , 1575-1585
Open AccessThe Toll‐like receptor 7/8‐ligand resiquimod (R‐848) primes human neutrophils for leukotriene B 4 , prostaglandin E 2 and platelet‐activating factor biosynthesis
Toll‐like receptors (TLR) recognize pathogen‐associated molecular patterns and play important roles in the innate immune system. While single‐stranded viral RNA is the natural ligand of TLR7/TLR8, the imidazoquinoline resiquimod (R‐848) is recognized as a potent synthetic agonist of TLR7/TLR8. We investigated the effects of TLR7/8 activation on lipid mediator production in polymorphonuclear leukocytes exposed to R‐848. Although R‐848 had minimal effects by itself, it strongly enhanced leukotriene B 4 formation on subsequent stimulation by fMLP, platelet‐activating factor, and the ionophore A23187. R‐848 acted via TLR8 but not TLR7 as shown by the lack of effect of the TLR7‐specific ligand imiquimod. Priming with R‐848 also resulted in enhanced arachidonic acid release and platelet‐activating factor formation following fMLP stimulation, as well as enhanced prostaglandin E 2 synthesis following the addition of arachidonic acid. Western blot analysis demonstrated that R‐848 induced the phosphorylation of the cytosolic phospholipase A 2 α, promoted 5‐lipoxygenase translocation and potently stimulated the expression of the type 2 cyclooxygenase. Bafilomycin A1, an inhibitor of endosomal acidification, efficiently inhibited all R‐848‐induced effects. These studies demonstrate that TLR8 signaling strongly promotes inflammatory lipid mediator biosynthesis and provide novel insights on innate immune response to viral infections.—Hattermann K., Picard, S., Borgeat, M., Leclerc, P., Pouliot, M., Borgeat P. The Toll‐like receptor 7/8‐ligand re‐siquimod (R‐848) primes human neutrophils for leuko‐triene B4, prostaglandin E2 and platelet‐activating factor biosynthesis. FASEB J. 21, 1575–1585 (2007)
- Open Access
- 1 October 2006
- Published by Wiley in British Journal of Pharmacology
- Vol. 149 (4) , 385-392
Effects of pyrrophenone, an inhibitor of group IVA phospholipase A2, on eicosanoid and PAF biosynthesis in human neutrophils
Background and Purpose: The biosynthesis of leukotrienes (LT) and platelet‐activating factor (PAF) involves the release of their respective precursors, arachidonic acid (AA) and lyso‐PAF by the group IVA PLA2 (cPLA2α). This paper aims at characterizing the inhibitory properties of the cPLA2α inhibitor pyrrophenone on eicosanoids and PAF in human neutrophils (PMN).Experimental Approach: Freshly isolated human PMN were activated with physiological and pharmacological agents (fMLP, PAF, exogenous AA, A23187 and thapsigargin) in presence and absence of the cPLA2α inhibitor pyrrophenone and biosynthesis of LT, PAF, and PGE2 was measured.Key Results: Pyrrophenone potently inhibited LT, PGE2 and PAF biosynthesis in PMN with IC50s in the range of 1–20 nM. These inhibitory effects of pyrrophenone were specific (the consequence of substrate deprivation), as shown by the reversal of inhibition by exogenous AA and lyso‐PAF. Comparative assessment of pyrrophenone, methyl‐arachidonoyl‐fluoro‐phosphonate (MAFP) and arachidonoyl‐trifluoromethylketone (AACOCF3) demonstrated that pyrrophenone was more specific and 100‐fold more potent than MAFP and AACOCF3 for the inhibition of LT biosynthesis in A23187‐activated PMN. The inhibitory effect of pyrrophenone on LT biosynthesis was reversible as LT biosynthesis was recovered when pyrrophenone‐treated PMN were washed with autologous plasma. No alteration of phospholipase D (PLD) activity in fMLP‐activated PMN was observed with up to 10 μM pyrrophenone, suggesting that the cPLA2α inhibitor does not directly inhibit PLD.Conclusions and Implications: Pyrrophenone is a more potent and specific cPLA2α inhibitor than MAFP and AACOCF3 and represents an excellent pharmacological tool to investigate the biosynthesis and the biological roles of eicosanoids and PAF.British Journal of Pharmacology (2006) 149, 385–392. doi:10.1038/sj.bjp.0706879
- 1 October 2006
- Published by Wiley in British Journal of Pharmacology
- Vol. 149 (4) , 385-392
Open AccessEffects of pyrrophenone, an inhibitor of group IVA phospholipase A2, on eicosanoid and PAF biosynthesis in human neutrophils
Background and Purpose: The biosynthesis of leukotrienes (LT) and platelet‐activating factor (PAF) involves the release of their respective precursors, arachidonic acid (AA) and lyso‐PAF by the group IVA PLA2 (cPLA2α). This paper aims at characterizing the inhibitory properties of the cPLA2α inhibitor pyrrophenone on eicosanoids and PAF in human neutrophils (PMN).Experimental Approach: Freshly isolated human PMN were activated with physiological and pharmacological agents (fMLP, PAF, exogenous AA, A23187 and thapsigargin) in presence and absence of the cPLA2α inhibitor pyrrophenone and biosynthesis of LT, PAF, and PGE2 was measured.Key Results: Pyrrophenone potently inhibited LT, PGE2 and PAF biosynthesis in PMN with IC50s in the range of 1–20 nM. These inhibitory effects of pyrrophenone were specific (the consequence of substrate deprivation), as shown by the reversal of inhibition by exogenous AA and lyso‐PAF. Comparative assessment of pyrrophenone, methyl‐arachidonoyl‐fluoro‐phosphonate (MAFP) and arachidonoyl‐trifluoromethylketone (AACOCF3) demonstrated that pyrrophenone was more specific and 100‐fold more potent than MAFP and AACOCF3 for the inhibition of LT biosynthesis in A23187‐activated PMN. The inhibitory effect of pyrrophenone on LT biosynthesis was reversible as LT biosynthesis was recovered when pyrrophenone‐treated PMN were washed with autologous plasma. No alteration of phospholipase D (PLD) activity in fMLP‐activated PMN was observed with up to 10 μM pyrrophenone, suggesting that the cPLA2α inhibitor does not directly inhibit PLD.Conclusions and Implications: Pyrrophenone is a more potent and specific cPLA2α inhibitor than MAFP and AACOCF3 and represents an excellent pharmacological tool to investigate the biosynthesis and the biological roles of eicosanoids and PAF.British Journal of Pharmacology (2006) 149, 385–392. doi:10.1038/sj.bjp.0706879
- Open Access
- 24 February 2006
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 79 (5) , 1043-1051
Inhibition of platelet-activating factor biosynthesis by adenosine and histamine in human neutrophils: involvement of cPLA2α and reversal by lyso-PAF
Leukotrienes (LT) and platelet-activating factor (PAF) are important lipid mediators of inflammation. We and others reported previously that autacoids such as adenosine, histamine, prostaglandin E2, and β-adrenergic agents inhibit LT biosynthesis in activated human polymorphonuclear leukocytes (PMN). In this study, we demonstrate that CGS-21680 (a selective agonist of the adenosine A2A receptor) and histamine also potently inhibit PAF biosynthesis in agonist [formyl Met-Leu-Phe (fMLP)]- and thapsigargin-activated human PMN. The observed inhibitions of PAF biosynthesis were reversed effectively by exogenous 1-O-alkyl-lyso-sn-glyceryl-3-phosphocholine (lyso-PAF), suggesting that these effects of CGS-21680 and histamine implicate the blockade of cytosolic phospholipase A2α (cPLA2α) activity and lyso-PAF release and that the acetyl-coenzyme A/lyso-PAF acetyl transferase is not inhibited by the autacoids. Accordingly, the cPLA2α inhibitor pyrrophenone completely blocked PAF formation, and lyso-PAF similarly prevented this effect of pyrrophenone. The inhibitory effects of CGS-21680 and histamine on PAF biosynthesis were prevented by the protein kinase A inhibitor H-89, supporting roles for the Gs-coupled receptors A2A and H2, respectively, and cyclic adenosine monophosphate in the inhibitory mechanism. The fMLP-induced phosphorylations of p38 and extracellular signal-regulated kinase 1/2 were not altered significantly by the CGS-21680, indicating that inhibition of these kinases is not involved in the inhibitory effect of the adenosine A2A receptor ligand on LT and PAF biosynthesis. These data further emphasize the multiple and potent inhibitory effects of adenosine and histamine on leukocyte functions, in particular, on the biosynthesis of two classes of important lipid mediators and their putative regulatory roles in immune processes in health and diseases.
- 24 February 2006
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 79 (5) , 1043-1051
Open AccessInhibition of platelet-activating factor biosynthesis by adenosine and histamine in human neutrophils: involvement of cPLA2α and reversal by lyso-PAF
Leukotrienes (LT) and platelet-activating factor (PAF) are important lipid mediators of inflammation. We and others reported previously that autacoids such as adenosine, histamine, prostaglandin E2, and β-adrenergic agents inhibit LT biosynthesis in activated human polymorphonuclear leukocytes (PMN). In this study, we demonstrate that CGS-21680 (a selective agonist of the adenosine A2A receptor) and histamine also potently inhibit PAF biosynthesis in agonist [formyl Met-Leu-Phe (fMLP)]- and thapsigargin-activated human PMN. The observed inhibitions of PAF biosynthesis were reversed effectively by exogenous 1-O-alkyl-lyso-sn-glyceryl-3-phosphocholine (lyso-PAF), suggesting that these effects of CGS-21680 and histamine implicate the blockade of cytosolic phospholipase A2α (cPLA2α) activity and lyso-PAF release and that the acetyl-coenzyme A/lyso-PAF acetyl transferase is not inhibited by the autacoids. Accordingly, the cPLA2α inhibitor pyrrophenone completely blocked PAF formation, and lyso-PAF similarly prevented this effect of pyrrophenone. The inhibitory effects of CGS-21680 and histamine on PAF biosynthesis were prevented by the protein kinase A inhibitor H-89, supporting roles for the Gs-coupled receptors A2A and H2, respectively, and cyclic adenosine monophosphate in the inhibitory mechanism. The fMLP-induced phosphorylations of p38 and extracellular signal-regulated kinase 1/2 were not altered significantly by the CGS-21680, indicating that inhibition of these kinases is not involved in the inhibitory effect of the adenosine A2A receptor ligand on LT and PAF biosynthesis. These data further emphasize the multiple and potent inhibitory effects of adenosine and histamine on leukocyte functions, in particular, on the biosynthesis of two classes of important lipid mediators and their putative regulatory roles in immune processes in health and diseases.
- 12 December 2005
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 393 (1) , 211-218
5-Lipoxygenase-activating protein homodimer in human neutrophils: evidence for a role in leukotriene biosynthesis
FLAP (5-lipoxygenase-activating protein) is a nuclear transmembrane protein involved in the biosynthesis of LTs (leukotrienes) and other 5-LO (5-lipoxygenase) products. However, little is known about its mechanism of action. In the present study, using cross-linkers, we demonstrate that FLAP is present as a monomer and a homodimer in human PMN (polymorphonuclear cells). The functional relevance of the FLAP dimer in LT biosynthesis was assessed in different experimental settings. First, the 5-LO substrate AA (arachidonic acid) concomitantly disrupted the FLAP dimer (at ≥10 μM) and inhibited LT biosynthesis. Secondly, using Sf9 cells expressing active and inactive FLAP mutants and 5-LO, we observed that the FLAP mutants capable of supporting 5-LO product biosynthesis also form the FLAP dimer, whereas inactive FLAP mutants do not. Finally, we showed that FLAP inhibitors such as MK-0591 which block LT biosynthesis in human PMN, disrupt the FLAP dimer in PMN membranes with a similar IC50. The present study demonstrates that LT biosynthesis in intact cells not only requires the presence of FLAP but its further organization into a FLAP homodimer.
- 12 December 2005
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 393 (1) , 211-218
5-Lipoxygenase-activating protein homodimer in human neutrophils: evidence for a role in leukotriene biosynthesis
FLAP (5-lipoxygenase-activating protein) is a nuclear transmembrane protein involved in the biosynthesis of LTs (leukotrienes) and other 5-LO (5-lipoxygenase) products. However, little is known about its mechanism of action. In the present study, using cross-linkers, we demonstrate that FLAP is present as a monomer and a homodimer in human PMN (polymorphonuclear cells). The functional relevance of the FLAP dimer in LT biosynthesis was assessed in different experimental settings. First, the 5-LO substrate AA (arachidonic acid) concomitantly disrupted the FLAP dimer (at ≥10 μM) and inhibited LT biosynthesis. Secondly, using Sf9 cells expressing active and inactive FLAP mutants and 5-LO, we observed that the FLAP mutants capable of supporting 5-LO product biosynthesis also form the FLAP dimer, whereas inactive FLAP mutants do not. Finally, we showed that FLAP inhibitors such as MK-0591 which block LT biosynthesis in human PMN, disrupt the FLAP dimer in PMN membranes with a similar IC50. The present study demonstrates that LT biosynthesis in intact cells not only requires the presence of FLAP but its further organization into a FLAP homodimer.
- Open Access
- 1 February 2004
- Published by Wiley in British Journal of Pharmacology
- Vol. 141 (4) , 552-561
Histamine‐induced inhibition of leukotriene biosynthesis in human neutrophils: involvement of the H2 receptor and cAMP
Histamine is generally regarded as a pro‐inflammatory mediator in diseases such as allergy and asthma. A growing number of studies, however, suggest that this autacoid is also involved in the downregulation of human polymorphonuclear leukocyte (PMN) functions and inflammatory responses through activation of the Gs‐coupled histamine H2 receptor. We report here that histamine inhibits thapsigargin‐ and ligand (PAF and fMLP)‐induced leukotriene (LT) biosynthesis in human PMN in a dose‐dependent manner. The suppressive effect of histamine on LT biosynthesis was abrogated by the histamine H2 receptor antagonists cimetidine, ranitidine, and tiotidine. In contrast, the histamine H1, H3, and H4 receptor antagonists used in this study were ineffective in counteracting the inhibitory effect of histamine on the biosynthesis of LT in activated human PMN. The inhibition of LT biosynthesis by histamine was characterized by decreased arachidonic acid release and 5‐lipoxygenase translocation to the nuclear membrane. Incubation of PMN with the cAMP‐dependent protein kinase (PKA) inhibitor N‐[2‐(p‐bromocinnamylamino)ethyl]‐5‐isoquinoline‐sulfonamide prevented the inhibitory effect of histamine on LT biosynthesis, suggesting an important role for PKA in this effect of histamine on LT biosynthesis in PMN. These data provide the first evidences that, similarly to adenosine and prostaglandin E2, histamine is a potent suppressor of LT biosynthesis, and support the concept that histamine may play a dual role in the regulation of inflammation. British Journal of Pharmacology (2004) 141, 552–561. doi:10.1038/sj.bjp.0705654
- 1 February 2004
- Published by Wiley in British Journal of Pharmacology
- Vol. 141 (4) , 552-561
Open AccessHistamine‐induced inhibition of leukotriene biosynthesis in human neutrophils: involvement of the H2 receptor and cAMP
Histamine is generally regarded as a pro‐inflammatory mediator in diseases such as allergy and asthma. A growing number of studies, however, suggest that this autacoid is also involved in the downregulation of human polymorphonuclear leukocyte (PMN) functions and inflammatory responses through activation of the Gs‐coupled histamine H2 receptor. We report here that histamine inhibits thapsigargin‐ and ligand (PAF and fMLP)‐induced leukotriene (LT) biosynthesis in human PMN in a dose‐dependent manner. The suppressive effect of histamine on LT biosynthesis was abrogated by the histamine H2 receptor antagonists cimetidine, ranitidine, and tiotidine. In contrast, the histamine H1, H3, and H4 receptor antagonists used in this study were ineffective in counteracting the inhibitory effect of histamine on the biosynthesis of LT in activated human PMN. The inhibition of LT biosynthesis by histamine was characterized by decreased arachidonic acid release and 5‐lipoxygenase translocation to the nuclear membrane. Incubation of PMN with the cAMP‐dependent protein kinase (PKA) inhibitor N‐[2‐(p‐bromocinnamylamino)ethyl]‐5‐isoquinoline‐sulfonamide prevented the inhibitory effect of histamine on LT biosynthesis, suggesting an important role for PKA in this effect of histamine on LT biosynthesis in PMN. These data provide the first evidences that, similarly to adenosine and prostaglandin E2, histamine is a potent suppressor of LT biosynthesis, and support the concept that histamine may play a dual role in the regulation of inflammation. British Journal of Pharmacology (2004) 141, 552–561. doi:10.1038/sj.bjp.0705654
- 1 January 2001
- Published by Wiley in Drug Development Research
- Vol. 52 (1-2) , 397-405
Suppressive effects of adenosine on the 5‐lipoxygenase pathway in human polymorphonuclear leukocytes
Leukotrienes are potent mediators of inflammation and host defense. They are also involved in inflammatory and allergic diseases. While numerous studies have investigated the stimulatory mechanisms of leukotriene biosynthesis in phagocytes by inflammatory agents (chemoattractants, cytokines, etc.), the mechanisms responsible for the physiological downregulation of leukotriene biosynthesis have been the subject of very few investigations so far. It has, however, been reported that E‐type prostaglandins are potent inhibitors of leukotriene biosynthesis in chemoattractant‐stimulated neutrophils and we have recently shown with in vitro studies that endogenous adenosine is a potent inhibitor of leukotriene biosynthesis by neutrophils. The present review summarizes our studies demonstrating that adenosine downregulates leukotriene biosynthesis via an interaction with the adenosine A2a receptor on neutrophils; studies aimed at defining the mechanisms of action of adenosine in this process have demonstrated that adenosine inhibits the translocation of the cytosolic enzyme 5‐lipoxygenase to nuclear structures, a process required for leukotriene biosynthesis in neutrophils. Our studies also demonstrated that exposure of human neutrophils to the adenosine A2a receptor agonist CGS‐21680 result in a profound inhibition of the release of arachidonic acid upon cell stimulation. While the previously reported inhibitory effect of adenosine on calcium influx elicited in ligand‐activated neutrophils does not appear to be involved in the inhibitory effects of adenosine on leukotriene biosynthesis, strong evidence supports the implication of elevation of intracellular cyclic AMP concentration both in the inhibition of 5‐lipoxygenase translocation and arachidonic acid release. Drug Dev. Res. 52:397–405, 2001.
- 1 January 2001
- Published by Wiley in Drug Development Research
- Vol. 52 (1-2) , 397-405
Suppressive effects of adenosine on the 5‐lipoxygenase pathway in human polymorphonuclear leukocytes
Leukotrienes are potent mediators of inflammation and host defense. They are also involved in inflammatory and allergic diseases. While numerous studies have investigated the stimulatory mechanisms of leukotriene biosynthesis in phagocytes by inflammatory agents (chemoattractants, cytokines, etc.), the mechanisms responsible for the physiological downregulation of leukotriene biosynthesis have been the subject of very few investigations so far. It has, however, been reported that E‐type prostaglandins are potent inhibitors of leukotriene biosynthesis in chemoattractant‐stimulated neutrophils and we have recently shown with in vitro studies that endogenous adenosine is a potent inhibitor of leukotriene biosynthesis by neutrophils. The present review summarizes our studies demonstrating that adenosine downregulates leukotriene biosynthesis via an interaction with the adenosine A2a receptor on neutrophils; studies aimed at defining the mechanisms of action of adenosine in this process have demonstrated that adenosine inhibits the translocation of the cytosolic enzyme 5‐lipoxygenase to nuclear structures, a process required for leukotriene biosynthesis in neutrophils. Our studies also demonstrated that exposure of human neutrophils to the adenosine A2a receptor agonist CGS‐21680 result in a profound inhibition of the release of arachidonic acid upon cell stimulation. While the previously reported inhibitory effect of adenosine on calcium influx elicited in ligand‐activated neutrophils does not appear to be involved in the inhibitory effects of adenosine on leukotriene biosynthesis, strong evidence supports the implication of elevation of intracellular cyclic AMP concentration both in the inhibition of 5‐lipoxygenase translocation and arachidonic acid release. Drug Dev. Res. 52:397–405, 2001.
- 1 January 1998
- Published by Springer Nature
- Vol. 105, 201-207
Measurements of Prostanoids, Leukotrienes, and Isoprostanes by Enzyme Immunoassays
- 1 January 1998
- Published by Springer Nature
- Vol. 105, 201-207
Measurements of Prostanoids, Leukotrienes, and Isoprostanes by Enzyme Immunoassays